中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

868 records (took 0.023 seconds)

    T cell receptor-deficient T cell compositions
    11.
    发明授权
    T cell receptor-deficient T cell compositions 有权

    公开(公告)号：US12146158B2

    公开(公告)日：2024-11-19

    申请号：US18492221

    申请日：2023-10-23

    Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

    Inventor： Charles L. Sentman

    IPC: A61K35/12 ,  A61K39/00 ,  C12N5/0783

    Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

    ENGINEERED NEMO AND USES THEREOF
    16.
    发明公开
    ENGINEERED NEMO AND USES THEREOF 审中-公开

    公开(公告)号：US20240239851A1

    公开(公告)日：2024-07-18

    申请号：US18514761

    申请日：2023-11-20

    Applicant: TRUSTEES OF DARTMOUTH COLLEGE

    Inventor： Maria PELLEGRINI ,  Adam H. BARCZEWSKI ,  Gevorg GRIGORYAN

    IPC: C07K14/47

    CPC classification number: C07K14/4703

    Abstract: The present disclosure relates to a modified NEMO protein that, inter alia, allows for structural determination of the NEMO protein in the apo-form and in complex with a ligand by NMR or X-ray crystallography. The present disclosure also relates to the use of such modified NEMO proteins to screen and validate inhibitors of the interaction between NEMO and IKKα and/or IKKβ and for structure determination of NEMO in the apo-form and in complex with a ligand, preferably by NMR or X-ray crystallography.

    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
    17.
    发明公开
    VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF 审中-公开

    公开(公告)号：US20240228609A9

    公开(公告)日：2024-07-11

    申请号：US18476403

    申请日：2023-09-28

    Applicant: THE TRUSTEES OF DARTMOUTH COLLEGE

    Inventor： Randolph J. NOELLE ,  Lili WANG

    IPC: C07K16/28 ,  C07K14/705

    CPC classification number: C07K16/28 ,  C07K14/70503 ,  C07K16/2803 ,  A61K2039/505

    Abstract: The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and arthritic conditions such as RA.

Patent Agency Ranking